Osteoporosis International

, Volume 24, Issue 8, pp 2345–2352 | Cite as

Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy

  • R. Lindsay
  • N. B. Watts
  • J. L. Lange
  • P. D. Delmas
  • S. L. Silverman
Original Article

Abstract

Summary

This observational study showed that after 2 years, both risedronate and alendronate lowered the risk of hip and nonvertebral fractures compared with patients filling in a single bisphosphonate prescription.

Introduction

Post hoc analyses of the placebo-controlled trials suggested earlier effects for risedronate (6–12 months) than for alendronate (18–24 months). The present study extends our 1-year observational data that confirmed an earlier fracture reduction with risedronate and evaluated the absolute and relative effectiveness of alendronate and risedronate in clinical practice over 2 years.

Methods

We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population. Proportional hazard modeling compared the incidence of hip and nonvertebral fractures among the cohorts over 2 years after the initial prescription.

Results

In this cohort, we previously showed at 12 months a significant reduction of hip and nonvertebral fractures with risedronate but not with alendronate. At the end of 2 years, the cumulative incidence of hip fractures in the referent cohort was 1.9 %, and incidence of nonvertebral fractures was 6.3 %. Relative to the referent, 6 months after initiating therapy and continuing through 2 years, both risedronate and alendronate cohorts had approximately a 45 % lower incidence of hip fractures and a 30 % lower incidence of nonvertebral fractures.

Conclusion

These observations suggest that both risedronate and alendronate are effective at reducing the risk of hip and nonvertebral fracture after 2 years of treatment and support the post hoc analyses of placebo-controlled trials indicating an earlier effect of risedronate.

Keywords

Alendronate Effectiveness Fracture Osteoporosis Risedronate 

Abbreviations

CI

Confidence interval

ICD-9-CM

International Classification of Diseases, 9th Revision, Clinical Modification

References

  1. 1.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the US, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRefGoogle Scholar
  2. 2.
    MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213PubMedCrossRefGoogle Scholar
  3. 3.
    Tosteson A, Solomon D, King AB, Dawson-Hughes B, Burge R, Wong J (2005) Projections of osteoporosis fractures and costs by skeletal site in the USA. American Society for Bone and Mineral Research 27th Annual Meeting, Nashville, TN, USAGoogle Scholar
  4. 4.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077–2082PubMedCrossRefGoogle Scholar
  6. 6.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437–1443PubMedCrossRefGoogle Scholar
  7. 7.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
  8. 8.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91PubMedCrossRefGoogle Scholar
  9. 9.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
  10. 10.
    Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: The women's health initiative randomized trial. JAMA 290:1729–1738PubMedCrossRefGoogle Scholar
  11. 11.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  12. 12.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRefGoogle Scholar
  13. 13.
    Avorn J (2007) In defense of pharmacoepidemiology—embracing the yin and yang of drug research. N Engl J Med 357:2219–2221PubMedCrossRefGoogle Scholar
  14. 14.
    IMS Health. National Prescription Audit Plus, Plymouth Meeting, PA, USAGoogle Scholar
  15. 15.
    Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25–34PubMedCrossRefGoogle Scholar
  16. 16.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRefGoogle Scholar
  17. 17.
    Strom BL, Miettinen OS, Melmon KL (1984) Postmarketing studies of drug efficacy: how? Am J Med 77:703–708PubMedCrossRefGoogle Scholar
  18. 18.
    Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM et al (2007) Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol 166:348–354PubMedCrossRefGoogle Scholar
  19. 19.
    Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL et al (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2):S3–S13PubMedCrossRefGoogle Scholar
  20. 20.
    Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637–646PubMedCrossRefGoogle Scholar
  21. 21.
    Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E (2009) Risedronate and alendronate intervention over 3 years (reality): minimal differences in fracture risk reduction. Osteoporos Int 20:973–978PubMedCrossRefGoogle Scholar
  22. 22.
    Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE et al (2009) Risk of fracture in women treated with monthly oral Ibandronate or weekly bisphosphonates: the evaluation of Ibandronate efficacy (VIBE) database fracture study. Bone 44:758–765PubMedCrossRefGoogle Scholar
  23. 23.
    Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA et al (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23PubMedCrossRefGoogle Scholar
  24. 24.
    Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419PubMedCrossRefGoogle Scholar
  25. 25.
    Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928PubMedCrossRefGoogle Scholar
  26. 26.
    Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135PubMedCrossRefGoogle Scholar
  27. 27.
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group. J Clin Endocrinol Metab 85:4118–4124PubMedCrossRefGoogle Scholar
  28. 28.
    Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases. Mayo Clin Proc 81(8):1013–1022PubMedCrossRefGoogle Scholar
  29. 29.
    Gehlbach SH, Avrunin JS, Puleo E (2007) Trends in hospital care for hip fractures. Osteoporos Int 18:585–591PubMedCrossRefGoogle Scholar
  30. 30.
    Melton LJ 3rd, Kearns AE, Atkinson EJ, Bolander ME, Achenbach SJ, Huddleston JM et al (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687–694PubMedCrossRefGoogle Scholar
  31. 31.
    Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L et al (2005) Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20:898–905PubMedCrossRefGoogle Scholar
  32. 32.
    Siris ES, Pasquale MK, Wang Y, Watts NB (2011) Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008. J Bone Miner Res 26(1):3–11PubMedCrossRefGoogle Scholar
  33. 33.
    Ohsfeldt RL, Borisov NN, Sheer RL (2006) Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting. Osteoporos Int 17:252–258PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2013

Authors and Affiliations

  • R. Lindsay
    • 1
  • N. B. Watts
    • 2
  • J. L. Lange
    • 3
  • P. D. Delmas
    • 4
  • S. L. Silverman
    • 5
  1. 1.Helen Hayes HospitalWest HaverstrawUSA
  2. 2.Mercy Health Osteoporosis and Bone Health ServicesCincinnatiUSA
  3. 3.Procter & GambleMasonUSA
  4. 4.INSERM Unit 403Université Claude Bernard Lyon 1LyonFrance
  5. 5.Cedars-Sinai Medical Center and University of CaliforniaLos AngelesUSA

Personalised recommendations